why choose us

Clinical Trials Search

Showing 8,900 of 132,366 result(s)
Effect of the Erchonia® LunulaLaser™ for the Treatment of Toenail Onychomycosis

Status: Completed

Condition: Onychomycosis of Toenail

Interventions: 405nm violet and 635nm red laser light therapy.

Date: 2023-08-17

Use of Antibiotic Based Irrigation for Ureteroscopic Treatment of Urolithiasis

Status: NOT_YET_RECRUITING

Condition: Urinary Tract Infections

Interventions: Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy

Date: 2023-08-17

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Status: NOT_YET_RECRUITING

Condition: Lumbar Spinal Stenosis

Interventions: Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.

Date: 2023-08-17

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Status: Completed

Condition: Diffuse Astrocytoma, IDH-Mutant

Interventions: NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).

Date: 2023-08-17

Effects of Clear Speech on Listening Effort and Memory in Sentence Processing

Status: Completed

Condition: Speech

Interventions: The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-synt

Date: 2023-08-17

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients

Status: NOT_YET_RECRUITING

Condition: Carcinoma, Non-Small-Cell Lung

Interventions: Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles.
Durvalumab will also be given during the maintenance phase q4w

Date: 2023-08-17

Early Parkinson's Disease Monotherapy With CVN424

Status: Completed

Condition: Parkinson Disease

Interventions: Participants will receive 1 CVN424 tablet (150 mg) per day.

Date: 2023-08-17

Integrated Platform for Measuring and Reducing Symptoms of Autism Spectrum Disorder

Status: Completed

Condition: Autism Spectrum Disorder

Interventions: The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.

Date: 2023-08-17

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Status: Completed

Condition: Non Small Cell Lung Cancer

Interventions: Lorlatinib 100 mg orally daily

Date: 2023-08-17